Treating patients with multiple sclerosis during the COVID-19 pandemic: Assessing the expert recommendations.
作者信息
Guevara Carlos, Villa Eduardo, Rosas Carlos Silva, Diaz Violeta, Naves Rodrigo
机构信息
Faculty of Medicine, Hospital Clínico José Joaquín Aguirre, Universidad de Chile, Santos Dumont 999, Santiago, Chile.
Faculty of Medicine, Hospital Clínico José Joaquín Aguirre, Universidad de Chile, Santos Dumont 999, Santiago, Chile.
出版信息
Mult Scler Relat Disord. 2020 Aug;43:102224. doi: 10.1016/j.msard.2020.102224. Epub 2020 May 23.
Abstract
摘要
相似文献
1
Treating patients with multiple sclerosis during the COVID-19 pandemic: Assessing the expert recommendations.
Mult Scler Relat Disord. 2020 Aug;43:102224. doi: 10.1016/j.msard.2020.102224. Epub 2020 May 23.
2
B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran.
Mult Scler Relat Disord. 2020 Aug;43:102195. doi: 10.1016/j.msard.2020.102195. Epub 2020 May 13.
3
COVID-19 will change MS care forever - No.
Mult Scler. 2020 Sep;26(10):1149-1151. doi: 10.1177/1352458520929971. Epub 2020 Jun 22.
4
Impact of coronavirus disease (COVID-19) pandemic on multiple sclerosis care.
Clin Neurol Neurosurg. 2020 Oct;197:106203. doi: 10.1016/j.clineuro.2020.106203. Epub 2020 Sep 2.
5
Patients with MS treated with immunosuppressive agents: Across the COVID-19 spectrum.
Rev Neurol (Paris). 2020 Jun;176(6):523-525. doi: 10.1016/j.neurol.2020.04.009. Epub 2020 Apr 27.
6
Favorable outcome after COVID-19 infection in a multiple sclerosis patient initiated on ocrelizumab during the pandemic.
Mult Scler Relat Disord. 2020 Aug;43:102222. doi: 10.1016/j.msard.2020.102222. Epub 2020 May 23.
7
The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic.
Mult Scler Relat Disord. 2020 Aug;43:102174. doi: 10.1016/j.msard.2020.102174. Epub 2020 May 12.
8
COVID-19 pandemic: The experience of a multiple sclerosis centre in Chile.
Mult Scler Relat Disord. 2020 Jul;42:102204. doi: 10.1016/j.msard.2020.102204. Epub 2020 May 16.
9
COVID-19 in MS: Initial observations from the Pacific Northwest.
Neurol Neuroimmunol Neuroinflamm. 2020 May 26;7(5). doi: 10.1212/NXI.0000000000000783. Print 2020 Sep 3.
10
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.
JAMA. 2019 Jan 15;321(2):175-187. doi: 10.1001/jama.2018.20588.
引用本文的文献
1
COVID-19 severity and outcome in multiple sclerosis: Results of a national, registry-based, matched cohort study.
Mult Scler Relat Disord. 2021 Oct;55:103217. doi: 10.1016/j.msard.2021.103217. Epub 2021 Aug 16.
2
Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement.
J Neuroimmunol. 2021 Aug 15;357:577627. doi: 10.1016/j.jneuroim.2021.577627. Epub 2021 Jun 7.
3
COVID-19 Outcomes in Patients Undergoing B Cell Depletion Therapy and Those with Humoral Immunodeficiency States: A Scoping Review.
Pathog Immun. 2021 May 14;6(1):76-103. doi: 10.20411/pai.v6i1.435. eCollection 2021.
4
COVID-19 illness and autoimmune diseases: recent insights.
Inflamm Res. 2021 Apr;70(4):407-428. doi: 10.1007/s00011-021-01446-1. Epub 2021 Feb 28.
5
Evaluating the perspective of patients with MS and related conditions on their DMT in relation to the COVID-19 pandemic in one MS centre in Australia.
Mult Scler Relat Disord. 2020 Nov;46:102516. doi: 10.1016/j.msard.2020.102516. Epub 2020 Sep 16.
本文引用的文献
1
An Italian programme for COVID-19 infection in multiple sclerosis.
Lancet Neurol. 2020 Jun;19(6):481-482. doi: 10.1016/S1474-4422(20)30147-2. Epub 2020 Apr 30.
2
The COVID-19 pandemic and the use of MS disease-modifying therapies.
Mult Scler Relat Disord. 2020 Apr;39:102073. doi: 10.1016/j.msard.2020.102073. Epub 2020 Mar 27.
3
COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?
Mult Scler Relat Disord. 2020 Jul;42:102120. doi: 10.1016/j.msard.2020.102120. Epub 2020 Apr 15.
4
Multiple sclerosis and the risk of infection: considerations in the threat of the novel coronavirus, COVID-19/SARS-CoV-2.
J Neurol. 2020 May;267(5):1567-1569. doi: 10.1007/s00415-020-09822-3.
5
Quarantine alone or in combination with other public health measures to control COVID-19: a rapid review.
Cochrane Database Syst Rev. 2020 Apr 8;4(4):CD013574. doi: 10.1002/14651858.CD013574.
6
Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic.
Neurology. 2020 Jun 2;94(22):949-952. doi: 10.1212/WNL.0000000000009507. Epub 2020 Apr 2.
7
Immunosuppression for hyperinflammation in COVID-19: a double-edged sword?
Lancet. 2020 Apr 4;395(10230):1111. doi: 10.1016/S0140-6736(20)30691-7. Epub 2020 Mar 24.
8
COVID-19: consider cytokine storm syndromes and immunosuppression.
Lancet. 2020 Mar 28;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0. Epub 2020 Mar 16.
9
COVID-19 in Latin America: The implications of the first confirmed case in Brazil.
Travel Med Infect Dis. 2020 May-Jun;35:101613. doi: 10.1016/j.tmaid.2020.101613. Epub 2020 Feb 29.
10
Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China.
Intensive Care Med. 2020 May;46(5):846-848. doi: 10.1007/s00134-020-05991-x. Epub 2020 Mar 3.
Zotero 插件